Accueil   Diary - News   All news Advanced BioDesign joins ENHPATHY consortium

Advanced BioDesign joins ENHPATHY consortium

 

Advanced BioDesign joins ENHPATHY consortium to increase its knowledge in genetic alterations in hematologic cancers

 

Consortium gathers 27 organizations from 11 countries to work on enhanceropathies; will receive €4M from European Commission over next four years


Lyon, France, January 21, 2020 – Advanced BioDesign, a French pre-clinical stage biotechnology company focused on the development of a new treatment against resistant cancers, today announces it has teamed up with 27 European academic and industrial organizations from 11 countries to form the  multidisciplinary science consortium, ENHPATHY.

 

Reas the press release